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I. INTRODUCTION
The American College of Cardiology/American Heart As-
sociation (ACC/AHA) Task Force on Practice Guidelines
was formed to gather information and make recommenda-
tions about appropriate use of technology for the diagnosis
and treatment of patients with cardiovascular disease. Per-
cutaneous coronary interventions (PCI) are an important
group of technologies in this regard. Although initially
limited to PTCA, and termed percutaneous transluminal
coronary angioplasty (PTCA), PCI now includes other new
techniques capable of relieving coronary narrowing. Accord-
ingly, in this document, rotational atherectomy, directional
atherectomy, extraction atherectomy, laser angioplasty, im-
plantation of intracoronary stents and other catheter devices
for treating coronary atherosclerosis are considered compo-
nents of PCI. In this context PTCA will be used to refer to
those studies using primarily PTCA while PCI will refer to
the broader group of percutaneous techniques. These new
technologies have impacted the effectiveness and safety
profile initially established for PTCA. Moreover, important
advances have occurred in the use of adjunctive medical
therapies such as glycoprotein (GP) IIb/IIIa receptor block-
ers. In addition, since publication of the previous Guidelines
in 1993, greater experience in the performance of PCI in
patients with acute coronary syndromes and in community
hospital settings has been gained. In view of these develop-
ments, further review and revision of the guidelines is
warranted. This document reflects the opinion of the third
ACC/AHA committee charged with revising the guidelines
for PTCA to include the broader group of technologies now
termed PCI.
Several issues relevant to the Committee’s process and the
interpretation of the Guidelines have been noted previously
and are worthy of restatement. First, PCI is a technique that
has been continually refined and modified; hence continued,
periodic Guideline revision is anticipated. Second, these
guidelines are to be viewed as broad recommendations to aid
in the appropriate application of PCI. Under unique cir-
cumstances, exceptions may exist. These Guidelines are
intended to complement, not replace, sound medical judg-
ment and knowledge. They are intended for operators who
possess the cognitive and technical skills for performing PCI
and assume that facilities and resources required to properly
perform PCI are available. As in the past, the indications are
categorized as Class I, II, or III based on a multifactorial
assessment of risk as well as expected efficacy viewed in the
context of current knowledge and the relative strength of
this knowledge. Initially, this document describes the back-
ground information that forms the foundation for specific
indications. Topics fundamental to coronary intervention
are reviewed followed by separate discussions relating to
unique technical and operational issues. Formal recom-
mendations for the use of angioplasty are included in
Section V. Indications are organized according to clinical
presentation. This format is designed to enhance the use-
fulness of this document for the assessment and care of
patients with coronary artery disease (CAD).
This document employs the ACC/AHA style classifica-
tion as Class I, II, or III. These classes summarize the
indications for PCI as follows:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure
or treatment is useful and effective.
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Class II: Conditions for which there is conflicting ev-
idence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/
treatment is not useful/effective, and in some
cases may be harmful.
The weight of evidence in support of the recommenda-
tion for each listed indication is presented as follows:
Level of Evidence A: Data derived from multiple ran-
domized clinical trials.
Level of Evidence B: Data derived from a single ran-
domized trial or nonrandomized
studies.
Level of Evidence C: Consensus opinion of experts.
The ACC/AHA Task Force on Practice Guidelines
makes every effort to avoid any actual or potential conflicts
of interest that might arise as a result of an outside
relationship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such relation-
ships that might be perceived as real or potential conflicts of
interest. These statements are reviewed by the parent task
force, reported orally to all members of the writing panel at
the first meeting, and updated as changes occur.
II. GENERAL CONSIDERATIONS AND BACKGROUND
More than 500,000 PCI procedures are performed yearly in
the U.S., and it has been estimated that more than
1,000,000 procedures are performed annually worldwide.
New coronary devices have expanded the clinical and
anatomical indications for revascularization initially limited
by balloon catheter angioplasty. For example, stents reduce
both the acute risk of major complications and late-term
restenosis. The success of new coronary devices in meeting
these goals is in part represented by the less frequent use of
PTCA alone (,30%) and the high (.70%) penetration of
coronary stenting in the current practice of interventional
cardiology. Atherectomy devices and stenting, associated
with improved acute angiographic and clinical outcomes
compared to PTCA, in specific subsets, continue to be
applied to a wider patient domain that includes multivessel
disease and complex coronary anatomy. However, strong
evidence (level A data from multiple randomized clinical
trials) is only available for stenting in selected patients
undergoing single-vessel PCI. These Guidelines will focus
on the Food and Drug Administration (FDA) approved
balloon-related and nonballoon coronary revascularization
devices.
III. OUTCOMES
The outcomes of coronary interventional procedures are
measured in terms of success and complications and are
related to the mechanisms of the employed devices, as well
as the clinical and anatomic patient-related factors. With
increased operator experience, new technology, and adjunc-
tive pharmacotherapy, the overall success and complication
rates of angioplasty have improved.
A. Definitions of PCI Success
The success of a PCI procedure may be defined by
angiographic, procedural, and clinical criteria.
1. Angiographic Success. A successful PCI produces sub-
stantial enlargement of the lumen at the target site. The
consensus definition prior to the widespread use of stents
was the achievement of a minimum stenosis diameter
reduction to ,50% in the presence of grade 3 TIMI flow
(assessed by angiography). However, with the advent of
advanced adjunct technology, including coronary stents, a
minimum stenosis diameter reduction to ,20% has been
the clinical benchmark of an optimal angiographic result.
2. Procedural Success. A successful PCI should achieve
angiographic success without in-hospital major clinical
complications (e.g., death, myocardial infarction [MI],
emergency coronary artery bypass surgery [CABG]) during
hospitalization. Although the occurrence of emergency
artery coronary bypass surgery and death are easily identified
end points, the definition of procedure-related MI has been
debated. The development of Q-waves in addition to a
threshold value of CK elevation has been commonly used.
However, the significance of enzyme elevations in the
absence of Q-waves remains a subject of investigation and
debate. Several reports have identified non–Q-wave MIs
with CK-MB elevations 3 to 5 times the upper limit of
normal as having clinical significance. Thus a significant
increase in CK-MB without Q-waves is considered by most
to qualify as an associated complication of PCI.
If serial determinations are performed after PCI, an
abnormally high value (CK-MB .1 times normal) can be
expected in 10 to 15% of PTCA procedures, 15 to 20% of
stent procedures, 25 to 35% of atherectomy procedures, and
.25% for any device used in saphenous vein grafts (SVGs)
or long lesions with a high atherosclerotic burden, even in
the absence of other signs and symptoms of MI. There is no
accepted consensus on what level of CK-MB index (with or
without clinical or electrocardiographic [ECG] findings) is
indicative of a clinically important MI following the inter-
ventional procedure. Cardiac troponin T and I have now
been introduced as measurements of myocardial necrosis
and have been proven to be more sensitive and specific than
CK-MB. However, prognostic criteria after PCI based on
troponin T and I have not yet been developed. The Writing
Committee recommends that CK-MB determination be
performed on all patients who have signs or symptoms
suggestive of MI following the procedure or in patients in
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whom there is angiographic evidence of abrupt vessel closure,
important side branch occlusion, or new and persistent slow
coronary flow. In patients in whom a clinically driven CK-MB
determination is made, a CK-MB of .3 times the upper limit
of normal would constitute a clinically significant MI.
3. Clinical Success. In the short term, a clinically success-
ful PCI includes anatomic and procedural success with relief
of signs and/or symptoms of myocardial ischemia after the
patient recovers from the procedure. The long-term clinical
success requires that the short-term clinical success remains
durable and that the patient has persistent relief of signs and
symptoms of myocardial ischemia for more than 6 months
after the procedure. Restenosis is the principal cause of lack
of long-term clinical success when a short-term clinical
success has been achieved.
B. Definitions of Procedural Complications
As outlined in the 1998 coronary interventional document,
procedural complications are divided into six basic catego-
ries: death, MI, emergency CABG, stroke, vascular access
site complications, and contrast agent nephropathy. Key
data elements and definitions to measure the clinical man-
agement and outcomes of patients undergoing diagnostic
catheterization and/or PCI have been defined in the Clin-
ical Data Standards document and the ACC-National
Cardiovascular Data Registry™ Catheterization Laboratory
Table 1. Definitions of Procedural Complications
Procedural Complications Definitions
Primary cause of death Patient died during this hospitalization
Periprocedural MI The NEW presence of an MI as documented by at least 1 of the following criteria:
1. Evolutionary ST-segment elevations, development of new Q-waves in 2 or more contiguous ECG leads,
or new or presumably new LBBB pattern on the ECG
2. Biochemical evidence of myocardial necrosis; this can be manifested as 1) CK-MB $3 3 the upper limit
of normal or if CK-MB not available (2) total CK $3 3 upper limit of normal. Because normal limits
of certain blood tests may vary, please check with your lab for normal limits for CK-MB and total CK
CABG during this admission If the patient had a CABG during this admission indicate the CABG status using the following categories:
I. Elective: The procedure could be deferred without increased risk of compromised cardiac outcome
II. Urgent: All of the following conditions are met:
A. Not elective
B. Not emergency
C. Procedure required during same hospitalization in order to minimize chance of further clinical
deterioration
III. Emergency: The patient’s clinical status includes any of the following:
A. Ischemic dysfunction (any of the following):
1. Ongoing ischemia including rest angina despite maximal medical therapy (medical and/or IABP)
2. Acute evolving MI within 24 hours before intervention
3. Pulmonary edema requiring intubation
B. Mechanical dysfunction (either of the following):
1. Shock with circulatory support
2. Shock without circulatory support
IV. Salvage: The patient is undergoing CPR en route to the Operating Room
CVA/Stroke Patient experienced a cerebrovascular accident (CVA) as documented by a loss of neurological function
caused by an ischemic event with residual symptoms at least 24 hours after onset
Vascular complications
Bleeding Blood loss at the site of arterial or venous access or due to perforation of a traversed artery or vein requiring
transfusion and/or prolonging the hospital stay, and/or causing a drop in hemoglobin .3.0 gm/dl.
Bleeding attributable to the vascular site could be retroperitoneal, a local hematoma .10 cm diameter or
external
Occlusion A total obstruction of the artery usually at the site of access requiring surgical repair. Occlusion is defined
as total obstruction of the artery by thrombus, dissection or other mechanism, usually at the site of
access, requiring surgical repair. Occlusion may be accompanied by absence of palpable pulse or Doppler
signal and associated with signs and symptoms of an ischemic limb requiring surgical intervention
Dissection A dissection occurred at the site of percutaneous entry. Dissection is defined as disruption of an arterial wall
resulting in splitting and separation of the intimal (or subintimal) layers
Pseudoaneurysm Pseudoaneurysm is defined as the occurrence of an aneurysmal dilatation of the artery at the site of catheter
entry demonstrated by arteriography or ultrasound
AV fistula AV fistula is defined as a connection between the access artery (e.g., femoral) and access vein (e.g., femoral)
that is demonstrated by an imaging study (arteriography or ultrasound) and most often characterized by a
continuous bruit
Renal failure After the lab visit—but before any subsequent lab visits only:
Indicate if the patient experienced acute renal insufficiency resulting in an increase in serum creatinine to
more than 2.0 mg/dl (or a 50% or greater increase over an abnormal baseline) measured prior to
procedure, or requiring dialysis
CABG 5 coronary artery bypass graft; CK 5 creatine kinase; CPR 5 cardiopulmonary resuscitation; ECG 5 electrocardiographic; IABP 5 intra-aortic balloon pump; LBBB 5
left bundle-branch block; MI 5 myocardial infarction.
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Module version 2.0. These rigorous definitions for key
adverse events are endorsed by this Writing Committee for
inclusion in the present PCI Guidelines (Table 1).
C. Acute Outcome
Improvements in balloon technology coupled with the
increased use of nonballoon devices, particularly stents
(which are effective in treating abrupt vessel closure) and GP
IIb/IIIa platelet receptor antagonists have favorably influ-
enced acute procedural outcome. This combined balloon/
device/pharmacologic approach to coronary intervention in
elective procedures has resulted in angiographic success rates
of 96 to 99%, with Q-wave MI rates of 1 to 3%, emergency
coronary bypass surgery rates of 0.2 to 3%, and unadjusted
in-hospital mortality rates of 0.5 to 1.4%.
D. Long-Term Outcome and Restenosis
Although improvements in technology, including stents
and new pharmacologic therapy, have resulted in an im-
proved acute outcome of the procedure, the impact of these
changes on long-term (5 to 10 years) outcome may be less
dramatic where factors such as advanced age, reduced left
ventricular (LV) function, and complex multivessel disease
in patients currently undergoing PCI may have a more
important influence. In addition, available data on long-
term outcome are mostly limited to patients undergoing
PTCA. Ten-year follow-up of the initial cohort of patients
treated with PTCA revealed an 89.5% survival rate (95% in
patients with single-vessel disease, 81% in patients with
multivessel disease). In patients within the 1985–1986
NHLBI PTCA Registry, 5-year survival was 92.9% for
patients with single-vessel disease, 88.5% for those with
2-vessel disease, and 86.5% for those with 3-vessel disease.
In patients with multivessel disease undergoing PTCA in
BARI, 5-year survival was 86.3% and infarct-free survival was
78.7%. Specifically, 5-year survival was 84.7% in patients with
3-vessel disease and 87.6% in patients with 2-vessel disease.
In addition to the presence of multivessel disease, other
clinical factors adversely impact late mortality. In random-
ized patients with treated diabetes in BARI, the 5-year
survival was 65.5%, and the cardiac mortality was 20.6% in
comparison to 5.8% cardiac mortality in patients without
treated diabetes, although among eligible but not random-
ized diabetic patients, the 5-year cardiac mortality was 7.5%.
In the 1985–1986 NHLBI PTCA Registry, 4-year survival
was significantly lower in women (89.2%) in comparison to
men (93.4%). In addition, although LV dysfunction was not
associated with an increase in in-hospital mortality or
nonfatal MI in patients undergoing PTCA in the same
registry, it was an independent predictor of a higher long-
term mortality.
A major determinant of event-free survival following
coronary intervention is the incidence of restenosis which
had, until the development of stents, remained fairly con-
stant, despite multiple pharmacologic and mechanical ap-
proaches to limit this process (Table 2). Depending on the
definition, (i.e., whether clinical or angiographic restenosis
or target lesion revascularization is measured), the incidence
of restenosis following coronary intervention had been 30 to
40%, and higher in certain clinical and angiographic subsets.
Although multiple clinical factors (diabetes, unstable
angina, acute MI, prior restenosis), angiographic factors
(proximal left anterior descending artery, small vessel diam-
eters, total occlusion, long lesion length, SVG), and proce-
dural factors (higher post-procedure percent diameter ste-
Table 2. Selected Trials of Pharmacologic and Mechanical Approaches to Limit Restenosis
Study Year N Agent
Restenosis Rate (%)
Placebo or Control Agent
Schwartz 1988 376 Aspirin and Dipyridamole 39 38
Ellis 1989 416 Heparin 37 41
Pepine 1990 915 Methylprednislone 39 40
CARPORT 1991 649 Vapiprost 19 21
O’Keefe 1991 197 Colchicine 22 22
MERCATOR 1992 735 Cilazapril 28 28
CAVEAT* 1993 500 DCA vs. PTCA 57 50
CCAT 1993 136 DCA vs. PTCA 43 46
Serruys 1993 658 Ketanserin 32 32
BENESTENT* 1994 520 Stent vs. PTCA 32 22
ERA 1994 458 Enoxaparin 51 52
Leaf 1994 551 Fish Oil 46 52
STRESS* 1994 410 Stent vs. PTCA 42 32
Weintraub 1994 404 Lovastatin 42 39
BOAT* 1996 492 DCA vs. PTCA 40 31
Wantanabe* 1996 118 Probucol 40 20
Tardif* 1997 317 Probucol 39 21
BENESTENT II* 1998 823 Stent vs. PTCA 31 17
TREAT* 1999 255 Tranilast 39 18
PRESTO* 2000 192 DCA and Tranilast 26 11
*p , 0.05.
DCA 5 Directional Coronary Atherectomy; PTCA 5 percutaneous transluminal coronary angioplasty.
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nosis, smaller minimal lumen diameter, and smaller acute
gain), have been associated with an increased incidence of
restenosis, the ability to integrate these factors and predict
the risk of restenosis in individual patients following the
procedure remains difficult. The most promising potential
approaches to favorably impact the restenosis process relate
to: 1) the ability to decrease elastic recoil and remodeling
using intracoronary stents, and 2) to the ability to reduce
intimal hyperplasia using catheter-based ionizing radiation.
More than 6,300 patients have been studied in 12 random-
ized clinical trials to assess the efficacy of PTCA vs. stents to
reduce restenosis (Table 3).
In addition, randomized studies in patients with in-stent
restenosis have shown that both intracoronary gamma and
beta radiation significantly reduced the rate of subsequent
angiographic and clinical restenosis by 30 to 50%.
E. Predictors of Success/Complications
1. Anatomic Factors. The risk of PTCA in the pre-stent
era relative to anatomic subsets has been identified in
previous NHLBI PTCA Registry data and by the ACC/
AHA Task Force. The lesion classification based on severity
of characteristics proposed in the past has been principally
altered using the present PCI techniques, which capitalize
on the ability of stents to manage initial and subsequent
complications of coronary interventions. As a result the
Committee has revised the previous ACC/AHA lesion
classification system to reflect low, moderate, and high risk
(Table 4) in accordance with the PCI Clinical Data Stan-
dards from the ACC-National Cardiovascular Data Regis-
try™.
2. Clinical Factors. Coexistent clinical conditions can
increase the complication rates for any given anatomic risk
factor. The clinical risk factors associated with in-hospital
adverse events have been further evaluated with additional
experience during the PCI era and summarized based on
odds ratio .2.0 or results of multivariate analysis (Table 5).
3. Risk of Death. In the majority of patients undergoing
elective PCI, death as a result of PCI is directly related to
the occurrence of coronary artery occlusion and is most
frequently associated with pronounced LV failure. The
clinical and angiographic variables associated with increased
mortality include advanced age, female gender, diabetes,
prior MI, multivessel disease, left main or equivalent coro-
nary disease, a large area of myocardium at risk, pre-existing
Table 3. Studies Comparing Balloon Angioplasty With Stents for Native Coronary Artery Lesions
Study Year
Follow-Up,
Month
N, Stent/
Angioplasty
Angiographic Restenosis, %
Target-Vessel
Revascularization (TVR), %
Death, MI,
or TVR, %
Stent Angioplasty p Value Stent Angioplasty p Value Stent Angioplasty
STRESS 1994 6 205/202 31.6 42.1 0.046 10.2 15.4 0.06 19.5 23.8
BENESTENT* 1996 12 259/257 — — — 10 21 0.001 23.2 31.5
TASC I 1995 6 270 (Overall)† 31 46 0.01 — — — — —
Versaci et al. 1997 12 60/60 19 40 0.02 6.6 22 — — —
STRESS II 1998 12 100/89 — — — 10 20 — 17 34
BENESTENT II 1998 6 413/410 16 31 ,0.001 8‡ 13.7 0.02 12.8 19.3
OCBAS 1998 7 57/59 18.8 16.6 — 17.5 9.2 — 19.2 16.9
EPISTENT§ 1998 6 1603/796 — — — 8.7 15.4 ,0.001 13 20.5
START 1999 6/48\ 229/223 22 37 ,0.002 12 24.6 ,0.002 16.9 29.9
OPUS 2000 6 479 (Overall) — — — 3.0 10.1 0.003 6.1 14.9
*Any event at one year; †122 patients in the TASC I trial had treated restenotic lesions; ‡any repeat procedure; §stent plus abciximab vs. percutaneous transluminal coronary
angioplasty plus abciximab; \6 months angiographic follow-up and 48 months clinical follow-up.
MI 5 myocardial infarction; dashes (—) 5 data not reported for that category. Data are for lesions in coronary arteries with vessel diameter $3.0 mm. Adapted from Suwaidi
MB, et al. JAMA 2000;284:1828–36.
Table 4. Lesion Classification System
Anatomic Risk Groups*
2000
PCI Stent Era
Low Risk
Discrete (length ,10 mm)
Concentric
Readily accessible
Nonangulated segment (,45°)
Smooth contour
Little or no calcification
Less than totally occlusive
Not ostial in location
No major side branch involvement
Absence of thrombus
Moderate Risk
Tubular (length 10–20 mm)
Eccentric
Moderate tortuosity of proximal segment
Moderately angulated segment (.45°, ,90°)
Irregular contour
Moderate or heavy calcification
Total occlusions ,3 months old
Ostial in location
Bifurcation lesions requiring double guidewires
Some thrombus present
High Risk
Diffuse (length .20 mm)
Excessive tortuosity of proximal segment
Extremely angulated segments .90°
Total occlusions .3 months old and/or bridging collaterals
Inability to protect major side branches
Degenerated vein grafts with friable lesions
*This classification of lesion risk is cited from the ACC-National Cardiovascular Data
Registry™ Catheterization Laboratory Module version 2.0. This classification scheme
is also cited in the ACC Clinical Data Standards.
PCI 5 percutaneous coronary interventions.
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impairment of LV or renal function, and collateral vessels
supplying significant areas of myocardium that originate
distal to the segment to be dilated (Table 5).
4. Women. In comparison to men, women undergoing
PCI are older and have a higher incidence of hypertension,
diabetes mellitus, hypercholesterolemia, and comorbid dis-
ease. Early reports of patients undergoing PTCA revealed a
lower procedural success rate in women; however, more
recent studies have noted similar angiographic outcome and
incidence of MI and emergency coronary bypass surgery in
women and men. Although reports have been inconsistent,
in several large-scale registries, in-hospital mortality is
significantly higher in women and an independent effect of
gender on acute mortality following PCI persists after
adjustments for the baseline higher-risk profile in women.
5. The Elderly Patient. Age .75 years is one of the major
clinical variables associated with increased risk of complica-
tions. In the elderly population, the morphologic and
clinical variables are compounded by advanced years with
the very elderly having the highest-risk of adverse outcomes.
In the stent era, procedural success rates and short-term
outcomes are comparable to those for nonoctogenarians.
Thus, with rare exception (primary PCI for cardiogenic
shock for patients .75 years), a separate category has not
been created in these Guidelines for the elderly. However,
their higher incidence of comorbidities should be taken into
account when considering the need for PCI.
6. Diabetes Mellitus. In the TIMI-IIB study of MI,
patients with diabetes mellitus had significantly higher
6-week (11.6% vs. 4.7%), 1-year (18.0% vs. 6.7%), and
3-year (21.6% vs. 9.6%) mortality rates compared to non-
diabetic patients. The BARI trial, in which stents and
abciximab were not used, showed that survival was better for
patients with treated diabetes undergoing CABG with an
arterial conduit than for those undergoing angioplasty.
Stenting decreases the need for target revascularization
Table 5. Clinical Risk Factors Associated With In-Hospital Adverse Events*
Variables Definitions
Age Date of birth as stated by the patient or family
Gender Male or female
LVEF-calculated Calculated by LV gram, echo, blood pool scan
LVEF-estimated Estimated by LV gram, echo, blood pool scan
No. of vessels .70% By angiography measured, quantified or estimated diameter stenosis; “vessel” defined as RCA and its
branches, proximal LAD (before 1st diagonal), mid/distal LAD and its branches, and Cx and its branches
Unstable angina Progressive or new onset or occurs at rest accompanied by ECG changes, hypotension or pulmonary
congestion
CCS Class IV Highest CCS angina class leading to hospital admission and/or intervention: 0 5 no angina by Hx
CHF Hx of CHF before intervention
MI at this admission Within 24 h of AMI
Previous MI .1 day; ,7 days of AMI
Urgency of the procedure Elective: patient clinically stable; procedure routinely scheduled
Urgent: unstable patient: procedure scheduled before discharge
Emergent/ongoing ischemia: ongoing ischemia including rest angina despite maximal therapy (medical or
IABP)
Emergent/salvage: arrest with CPR immediately before entering lab
Cardiogenic shock Hypoperfusion with SBP ,80 mm Hg and central filling pressure .20 mm Hg or cardiac index
,1.8 liters/min/m2; also present if inotropes or IABP needed to maintain these values
Preprocedural IABP/CPS IABP/CPS assisted device placed before intervention
Aortic valve disease Aortic valve area ,1.0 cm2 and/or Aortic regurgitation .21
Mitral regurgitation .21 Presence of mitral regurgitation .21
Diabetes (treated) Clinical diagnosis of diabetes treated either with oral agents or insulin with or without sequelae
PVD Presence of occlusive disease in the aorta, iliac, or femoral artery sufficient to cause symptoms
Stroke Hx of presence of fixed neurological deficit
Creatinine If creatinine preintervention known, list creatinine
Creatinine .2 mg/dl Creatinine .2 mg/dl known in past
Dialysis Patient on dialysis
Cholesterol .225 mg/dl (reduced risk) Measure cholesterol . 225 mg/dl before intervention
Same vessel intervention (reduced risk) Any previous intervention on same vessel
Type C lesions attempted Type A: concentric noncalcified, ,10 mm in length, not bifurcated or angulated. Type C: total occlusion.
Type B: all others (ACC/AHA)
LMCA attempted-unprotected Intervention involving all or part of LMCA
LMCA attempted-protected “Protected” LMCA stenosis by patent bypass conduit
Vein graft intervention Any intervention to SVG or IMA
Thrombus Intraluminal filling defect, haziness or contrast staining in artery before intervention
*Note: More than 50% of databases that evaluated the variable showed an odds ratio .2.0 or variable chosen on multivariable analysis. The definition of variables defined herein
varies slightly from those agreed upon in the ACC Clinical Data Standards.
AMI 5 acute myocardial infarction; CCS 5 Canadian Cardiovascular Society; CHF 5 congestive heart failure; CPR 5 cardiopulmonary resuscitation; CPS 5 cardiopulmonary
support; Cx 5 circumflex; ECG 5 electrocardiogram; Hx 5 history; IABP 5 intra-aortic balloon pump; IMA 5 internal mammary artery; LAD 5 left anterior descending coronary
artery; LMCA 5 left main coronary artery; LV 5 left ventricle; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PVD 5 peripheral vascular disease; RCA 5
right coronary artery; SBP 5 systolic blood pressure; SVG 5 saphenous vein graft. Adapted with permission from Block P, et al. J Am Coll Cardiol. 2000;32:275–82.
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procedures in diabetic patients compared with PTCA. The
efficacy of stenting with GP IIb/IIIa inhibitors was assessed
in the diabetic population compared to those without
diabetes in a substudy of the EPISTENT trial. Irrespective
of revascularization strategy abciximab significantly reduced
6-month death and MI rates in patients with diabetes for all
strategies. Likewise, 6-month target-vessel revascularization
was reduced in the stent/abciximab group approach.
7. Coronary Angioplasty After Coronary Artery Bypass
Surgery. Although speculated to be at higher risk, patients
having PCI of native vessels after prior coronary bypass
surgery have, in recent years, nearly equivalent interven-
tional outcomes and complication rates compared to pa-
tients having similar interventions without prior surgery.
For PCI of SVG, studies indicate that the rate of successful
angioplasty exceeds 90%, death ,1.2%, Q-wave MI
,2.5%. The incidence of non–Q-wave MI may be higher
than that associated with native coronary arteries.
Use of GP IIb/IIIa blockers has not been shown to
improve results of angioplasty in vein grafts. The native
vessels should be treated with PCI if feasible. Patients with
older and/or severely diseased SVGs may benefit from
elective repeat coronary artery bypass graft surgery rather
than PCI.
8. Specific Technical Considerations. Certain outcomes
of PCI may be specifically related to the technology utilized
for coronary recanalization. Antecedent unstable angina
appears to be a clinical predictor of slow flow and peripro-
cedural infarction following ablative technologies and direct
platelet activation has been demonstrated to occur with both
directional and rotational atherectomy.
Coronary perforation may occur more commonly follow-
ing the use of ablative technologies including rotational,
directional or extraction atherectomy, and excimer laser
coronary angioplasty. Coronary perforation complicates
PCI more frequently in the elderly and in women. While
20% of perforations may be secondary to the coronary
guidewire, most are related to the specific technology used.
9. Issues of Hemodynamic Support in High-Risk Angio-
plasty. Elective high-risk PCI can be performed safely
without intra-aortic balloon pump (IABP) or cardiopulmo-
nary support (CPS) in most circumstances. Emergency
high-risk PCI such as direct PCI for acute MI can usually
be performed without IABP or CPS. CPS for high-risk
PCI should be reserved only for patients at the extreme end
of the spectrum of hemodynamic compromise, such as those
patients with extremely depressed LV function and patients
in cardiogenic shock. However, it should be noted that in
patients with borderline hemodynamics, ongoing ischemia,
or cardiogenic shock, insertion of an intra-aortic balloon just
prior to coronary instrumentation has been associated with
improved outcomes. Furthermore, it is reasonable to obtain
vascular access in the contralateral femoral artery prior to the
procedure in patients in whom the risk of hemodynamic
compromise is high, thereby facilitating intra-aortic balloon
insertion, if necessary.
In patients having a higher-risk profile, consideration of
alternative therapies, particularly CABG, formalized surgi-
cal standby, or periprocedural hemodynamic support should
be addressed before proceeding with PCI.
F. Comparison With Bypass Surgery
The major advantage of PCI is its relative ease of use,
avoiding general anesthesia, thoracotomy, extracorporeal
circulation, CNS complications, and prolonged convales-
cence. Repeat PCI can be performed more easily than repeat
bypass surgery, and revascularization can be achieved more
quickly in emergency situations. The disadvantages of PCI
are early restenosis and the inability to relieve many totally
occluded arteries and/or those vessels with extensive athero-
sclerotic disease.
Coronary artery bypass surgery has the advantages of
greater durability (graft patency rates exceeding 90% at 10
years with arterial conduits) and more complete revascular-
ization irrespective of the morphology of the obstructing
atherosclerotic lesion. Generally speaking, the greater the
extent of coronary atherosclerosis and its diffuseness, the
more compelling the choice of CABG, particularly if LV
function is depressed. Patients with lesser extent of disease
and localized lesions are good candidates for endovascular
approaches.
Percutaneous transluminal coronary angioplasty and
CABG have been compared in many nonrandomized and
randomized studies. The most accurate comparisons of
outcomes are best made from prospective randomized trials
of patients suitable for either treatment. Although results of
these trials provide useful information for selection of
therapy in several patient subgroups, prior studies of PTCA
may not reflect outcome of current PCI practice, which
includes frequent use of stents and antiplatelet drugs.
Similarly, many previous studies of CABG may not reflect
outcome of current surgical practice in which arterial con-
duits are used whenever practicable. Beating heart bypass
operations are also employed for selected patients with
single-vessel disease with reduced morbidity. In addition,
patients are selected for PCI (with or without stenting)
because of certain lesion characteristics, and these anatom-
ical criteria are not required for CABG.
Despite these limitations, some generalizations can be
made from comparative trials of PTCA and CABG. First,
for most patients with single-vessel disease, late survival is
similar with either revascularization strategy, and this might
be expected given the generally good prognosis of most
patients with single-vessel disease managed medically.
In the ARTS trial, the first trial to compare stenting with
surgery, there was no significant difference in mortality
between PCI and surgical groups at one year. The main
difference compared to previous PTCA and CABG trials
was an approximate 50% reduction in the need for repeat
revascularization in a group randomized to PCI with stent
placement.
Direct comparison of initial strategies of PCI or CABG
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in patients with multivessel coronary disease is possible only
by randomized trials because of selection criteria of patients
for PCI. There have been five large (.300 patients)
randomized trials of PTCA versus CABG and two smaller
studies. These trials demonstrate that in appropriately
selected patients with multivessel coronary disease, an initial
strategy of standard PTCA yields similar overall outcomes
(e.g., death, MI) compared to initial revascularization with
coronary artery bypass.
An important exception to the conclusion of the relative
safety of PCI in multivessel disease is the subgroup of
patients with treated diabetes mellitus. Among treated
diabetic patients in BARI assigned to PTCA, 5-year sur-
vival was 65.5% compared to 80.6% for patients having
CABG (p 5 0.003); the improved outcome with CABG
was due to reduced cardiac mortality (5.8% vs. 20.6%, p 5
0.0003), which was confined to those receiving at least one
internal mammary artery graft.
G. Comparison With Medicine
There has been a considerable effort made to evaluate the
relative effectiveness of bypass surgery as compared to PCI
for coronary artery revascularization. In contrast to this, very
little effort has been directed toward comparing medical
therapy with PCI for the management of stable and
unstable angina.
Based on the limited data available from randomized
trials (Table 6) comparing medical therapy with PTCA, it
seems prudent to consider medical therapy for the initial
management of most patients with Canadian Cardiovascu-
lar Society Classification Class I and II and reserve PTCA
and CABG for those patients with more severe symptoms
and ischemia. The symptomatic individual patient who
wishes to remain physically active, regardless of age, will
more often require PCI. The results of the ACIP trial
indicate that higher-risk patients with asymptomatic isch-
emia and significant CAD who undergo complete revascu-
larization with CABG or PTCA may have a better outcome
as compared to those with medical management.
IV. INSTITUTIONAL AND OPERATOR COMPETENCY
A. Quality Assurance
A mechanism for valid peer review must be established
and ongoing at each institution performing PCI. Interven-
tional cardiology procedures are associated with complica-
tions that in general are inversely related to operator and
institutional volume. The mechanism for institutional re-
view should provide an opportunity for interventionalists as
well as physicians who do not perform angioplasty, but are
knowledgeable about it, to review overall results of the
program on a regular basis. The responsible supervising
authority should monitor the following issues as outlined in
Table 7.
The institutional credentialing committee should docu-
ment that an interventionalist wishing to start practice
meets the established training criteria, including those of the
ACC Task Force on Training in Cardiac Catheterization
and Interventional Cardiology. This Writing Committee
agrees with the ACC Task Force recommendations for the
Assessment and Maintenance of Proficiency in Coronary
Interventional Procedures. Institutions performing PCI
should meet the following standards as outlined in Tables 8
and 9.
B. Operator and Institutional Volume
The proliferation of small angioplasty or small surgical
programs to support such angioplasty programs is strongly
discouraged. Several studies have identified procedural vol-
ume as a determining factor for frequency of complications
with PCI.
Although some investigators have suggested that low
procedure volume does not contribute to poor outcomes,
these studies are small in number and underpowered for
analysis. Development of small cardiovascular surgical pro-
grams to support angioplasty is a poor use of resources that
will likely lead to suboptimal results.
Given the concerns regarding operator volume and sur-
gical standby, it is recommended that PCI be performed by
higher volume operators ($75 cases/year) with advanced
technical skills (e.g., subspecialty certification) at institu-
tions with fully equipped interventional laboratories and
experienced support staff. This setting will most often be in
a high-volume center (.400 cases/year) associated with an
on-site cardiovascular surgical program. Similar concerns
have been identified and supported by the Task Force for
Practice Guidelines for Coronary Angiography.
This Committee acknowledges that not every cardiologist
desiring to do PCI should perform these procedures and not
every hospital anxious to have an interventional program
should start one. This caveat is particularly true where there
are high-volume programs and operators nearby. In these
situations, operators should be subspecialty board certified.
Recommendations for PCI Institutional and Operator
Volumes at Centers With On-Site Cardiac Surgery
Class I
1. PCI done by operators with acceptable volume
(>75) at high-volume centers (>400). (Level of
Evidence: B)
Class IIa
1. PCI done by operators with acceptable volume
(>75) at low-volume centers (200 to 400). (Level of
Evidence: C)
2. PCI done by low volume operators (<75) at high-
volume centers (>400). Note: Ideally operators
with annual procedure volume <75 should only
work at institutions with an activity level of >600
procedures/year.* (Level of Evidence: C)
Class III
1. PCI done by low volume operators (<75) at low-
volume centers (200 to 400). Note: An institution
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Table 6. PCI Comparison With Medical Therapy
Study Year N Patient Population Treatment
Follow-
Up
Results
CommentsPCI
Medical
Therapy Significance
ACME 1992 212 Patients with single-
vessel disease
Medical therapy
vs. balloon
angioplasty
64% less
angina
46% less
angina
p , 0.01 The PTCA group had
less angina, better
exercise
performance and
more improvement
in quality of life
scores, but had
more complications
(emergency bypass 2
patients, MI in 5,
and repeat PTCA
in 16).
VA ACME 1997 328 Patients with
documented
chronic stable
angina
Medical therapy
vs. balloon
angioplasty
3 years 63% less
angina
48% less
angina
p 5 0.02 Among patients with
single-vessel disease,
the PTCA group
had less angina,
better exercise
performance, and
more improvement
in quality of life
scores.
227 single-vessel
disease
101 double-vessel
disease
RITA-2 1997 1018 53% with Class II
angina
47% with prior
angina
7% triple-vessel
disease
Medical therapy
vs. balloon
angioplasty
2.7 years 6.3% death
or MI
3.3% death or
MI
p 5 0.02 The PTCA group had
increased rates of
death and MI, but
had 7% less Class II
angina at 2 years
and longer exercise
treadmill test time
at 3 months.
ACIP 1997 558 Patients with
documented CAD
and asymptomatic
ischemia
183 angina-guided
drug therapy
183 angina plus
ischemia-guided
drug therapy
192 revascularization
by PTCA or
CABG
Angina-guided
drug therapy vs.
angina plus
ischemia-guided
drug therapy vs.
revascularization
2 years 4.7% death
or MI
8.8% death or
MI for
ischemia-
guided drug
therapy
12.1% death
or MI for
angina-
guided drug
therapy
p , 0.01 40% of patients had
previous MI, 23%
had prior PTCA or
CABG and 38%
had triple-vessel
disease.
AVERT 1999 341 Patients with stable
CAD, normal LV
function and
angina Class I/II
Medical therapy
with
atorvastatin vs
PTCA
18 months 21%
ischemic
events
13% ischemic
events
p 5 0.048 p 5 0.045 needed for
significance due to
interim analysis.
Patients required to
complete 4 minutes
on Bruce protocol.
Only 2 deaths
among 341 patients
in 18 months.
Significant
improvement in
angina in patients
treated with PTCA
compared with
medical therapy.
CABG 5 coronary artery bypass graft; CAD 5 coronary artery disease; LV 5 left ventricular; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention; PTCA 5
percutaneous transluminal coronary angioplasty.
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with a volume <200 procedures/year, unless in a
region that is underserved because of geography,
should carefully consider whether it should con-
tinue to offer service.* (Level of Evidence: C)
C. On-Site Cardiac Surgical Backup
Cardiac surgical backup for PCI has evolved from the
formal surgical standby in the 1980s to an informal arrange-
ment of first available operating room and, in some cases,
off-site surgical backup. With the advent of intracoronary
stenting, there has been a decrease in the need for emer-
gency coronary bypass, ranging between 0.4 and 2%.
1. Primary PCI Without On-Site Cardiac Surgery. Al-
though thrombolytic trials demonstrated that early reperfu-
sion saves myocardium and reduces mortality, the superior-
ity and greater applicability of primary PCI for the
treatment of acute MI has raised the question of whether
primary PCI should be performed at institutions with
diagnostic cardiac catheterization laboratories that do not
perform elective PCI or have on-site cardiac surgery. For
this reason, the establishment of PCI programs at institu-
tions without on-site cardiovascular surgery has been pro-
moted as necessary to maintain quality of care. It must be
realized that PCI in the early phase of an acute MI can be
difficult and requires even more skill and experience than
routine PCI in the stable patient. The need for an experi-
enced operator and experienced laboratory technical support
with availability of a broad range of catheters, guidewires,
stents, and other devices (e.g., IABP) that are required for
optimum results in an acutely ill patient is of major
importance (Table 9). If these complex patients are treated
by interventionalists with limited experience at institutions
with low volume, then the gains of early intervention may be
lost because of increased complications. In such circum-
stances, transfer to a center that routinely performs complex
PCI will often be a more effective and efficient course of
action. Thrombolysis is still an acceptable form of therapy
and is preferable to acute PCI by an inexperienced team.
Criteria have been suggested for the performance of
primary PCI at hospitals without on-site cardiac surgery
(Tables 9 and 10). Of note, large-scale registries have shown
an inverse relationship between the number of primary
angioplasty procedures performed and in-hospital mortality.
The data suggest that both door-to-balloon time and
in-hospital mortality are significantly lower in institutions
performing a minimum of 36 primary angioplasty proce-
dures per year. Communities may identify a unique qualified
and experienced center wherein the on-site intervention for
acute MI could be performed. Suboptimal results may relate
to operator/staff inexperience and capabilities and delays in
performing angioplasty for logistical reasons. From clinical
data and expert consensus, the Committee recommends
that primary PCI for acute MI performed at hospitals
without established elective PCI programs should be re-
stricted to those institutions with a proven plan for rapid
and effective PCI as well as rapid access to cardiac surgery in
a nearby facility (Table 11).
2. Elective PCI Without On-Site Surgery. Technical
improvements in interventional cardiology have led to the
development of elective angioplasty programs without on-
*Operators who perform ,75 procedures/year should develop a defined mentoring
relationship with a highly experienced operator who has an annual procedural volume
.150 procedures/year.
Table 8. Considerations for the Assessment and Maintenance of
Proficiency in Coronary Interventional Procedures
Institutions
c Quality assessment monitoring of privileges and risk stratified
outcomes
c Provide support for a quality assurance staff person (e.g., nurse) to
monitor complications
c Minimal institutional performance activity of 200 interventions per
year with the ideal minimum of 400 interventions per year
c Interventional program director who has a career experience of .500
PCI procedures and is board certified by ABIM in interventional
cardiology
c Facility and equipment requirements to provide high resolution
fluoroscopy and digital video processing
c Experienced support staff to respond to emergencies (See Section
IV, C. Need for Surgical Backup for discussion)
c Establishment of a mentoring program for operators who perform ,75
procedures per year by the individuals who perform $150 procedures
per year
Physicians
c Procedural volume of $75 per year
c Continuation of privileges based on outcome benchmark rates with
consideration of not granting privileges to operators who exceed
adjusted case mix benchmark complication rates for a 2-year-period
c Ongoing quality assessment comparing results with current
benchmarks with risk stratification of complication rates
c Board Certification by ABIM in interventional cardiology
ABIM 5 American Board of Internal Medicine; PCI 5 percutaneous coronary
intervention.
Table 7. Key Components of a Quality Assurance Program
Clinical proficiency c General indications/contraindications
c Institutional and individual operator
complication rates, mortality and
emergency bypass surgery
c Institutional and individual operator
procedure volumes
c Training and qualifications of support
staff
Equipment maintenance
and management
c Quality of laboratory facility (See
ACC/SCA&I Expert Consensus
Document on Cardiac Catheterization
Laboratory Standards)
Quality improvement
process
c Establishment of an active concurrent
database to track clinical and
procedural information as well as
patient outcomes for individual
operators and the institution. The
ACC-National Cardiovascular Data
Registry™ is strongly recommended
for this purpose
Radiation safety c Educational program in the diagnostic
use of X-ray
c Patient and operator radiation
exposure
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site surgical coverage. Caution is warranted before endors-
ing an unrestricted policy for PCI in hospitals without
appropriate facilities. Several outstanding and critically im-
portant clinical issues, such as timely management of
ischemic complications, adequacy of specialized post-
interventional care, logistics for managing cardiac surgical or
vascular complications and operator/laboratory volumes,
and accreditation must be addressed. At this time, the
Committee, therefore, continues to support the recommen-
dation that elective PCI should not be performed in
facilities without on-site cardiac surgery (Table 11). As with
many dynamic areas in interventional cardiology, these
recommendations may be subject to revision as clinical data
and experience increase.
Recommendations for PCI With and Without On-Site
Cardiac Surgery (Table 11)
Class I
1. Patients undergoing elective PCI in facilities with
on-site cardiac surgery. (Level of Evidence: B)
2. Patients undergoing primary PCI in facilities with
on-site cardiac surgery. (Level of Evidence: B)
Class IIb
1. Patients undergoing primary PCI in facilities with-
out on-site cardiac surgery, but with a proven plan
for rapid access (within 1 h) to a cardiac surgery
operating room in a nearby facility with appropriate
hemodynamic support capability for transfer. The
procedure should be limited to patients with ST-
segment elevation MI or new LBBB on ECG, and
done in a timely fashion (balloon inflation within
90 6 30 min of admission) by persons skilled in the
procedure (>75 PCIs/year) and only at facilities
performing a minimum of 36 primary PCI proce-
dures per year. (Level of Evidence: B)
Class III
1. Patients undergoing elective PCI in facilities with-
out on-site cardiac surgery. (Level of Evidence: C)
2. Patients undergoing primary PCI in facilities with-
out on-site cardiac surgery and without a proven plan
for rapid access (within 1 h) to a cardiac surgery
operating room in a nearby facility with appropriate
hemodynamic support capability for transfer or when
performed by lower skilled operators (<75 PCIs/year)
in a facility performing <36 primary PCI procedures
per year. (Level of Evidence: C)
V. INDICATIONS
A broad spectrum of clinical presentations exists wherein
patients may be considered candidates for PCI, ranging
from asymptomatic to severely symptomatic or unstable,
with variable degrees of jeopardized myocardium. Each time
that a patient is considered for revascularization, the poten-
tial risk and benefits of the particular procedure under
consideration must be weighed against alternative therapies.
Table 10. Patient Selection for Angioplasty and Emergency
Aortocoronary Bypass at Hospitals Without On-Site
Cardiac Surgery
Avoid intervention in hemodynamically stable patients with:
c Significant ($60%) stenosis of an unprotected left main (LM)
coronary artery upstream from an acute occlusion in the left coronary
system that might be disrupted by the angioplasty catheter
c Extremely long or angulated infarct-related lesions with TIMI grade 3
flow
c Infarct-related lesions with TIMI grade 3 flow in stable patients with
3-vessel disease
c Infarct-related lesions of small or secondary vessels
c Lesions in other than the infarct artery
Transfer for emergent aortocoronary bypass surgery patients with:
c High-grade residual left main or multivessel coronary disease and
clinical or hemodynamic instability
—After angioplasty or occluded vessels
—Preferably with intraaortic balloon pump support
Adapted with permission from Wharton TP Jr, McNamara NS, Fedele FA, Jacobs
MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute
myocardial infarction: experience at two community hospitals without cardiac surgery.
J Am Coll Cardiol 1999;33:1257–65.
Table 9. Criteria for the Performance Angioplasty at Hospitals
Without On-Site Cardiac Surgery
1. The operators must be experienced interventionalists who regularly
perform elective intervention at a surgical center ($75 cases/year).
The institution must perform a minimum of 36 primary PCI
procedures per year.
2. The nursing and technical catheterization laboratory staff must be
experienced in handling acutely ill patients and comfortable with
interventional equipment. They must have acquired experience in
dedicated interventional laboratories at a surgical center. They
participate in a 24-h, 365-day call schedule.
3. The catheterization laboratory itself must be well-equipped, with
optimal imaging systems, resuscitative equipment, intra-aortic.
balloon pump (IABP) support, and must be well-stocked with a
broad array of interventional equipment.
4. The cardiac care unit nurses must be adept in hemodynamic
monitoring and IABP management.
5. The hospital administration must fully support the program and
enable the fulfillment of the above institutional requirements.
6. There must be formalized written protocols in place for immediate
(within 1 h) and efficient transfer of patients to the nearest cardiac
surgical facility which are reviewed/tested on a regular (quarterly) basis.
7. Primary intervention must be performed routinely as the treatment
of choice around the clock for a large proportion of patients with
AMI, to ensure streamlined care paths and increased case volumes.
8. Case selection for the performance of primary angioplasty must be
rigorous. Criteria for the types of lesions appropriate for primary
angioplasty and for the selection for transfer for emergent
aortocoronary bypass surgery are shown in Table 10.
9. There must be an ongoing program of outcomes analysis and
formalized periodic case review.
10. Institutions should participate in a 3- to 6-month period of
implementation during which time development of a formalized
primary PCI program is instituted that includes establishing
standards, training staff, detailed logistic development, and creation
of a quality assessment and error management system.
Adapted with permission from Wharton TP Jr, McNamara NS, Fedele FA, Jacobs
MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute
myocardial infarction: experience at two community hospitals without cardiac surgery.
J Am Coll Cardiol 1999;33:1257–65.
AMI 5 acute myocardial infarction; IABP 5 intra-aortic balloon pump; PCI 5
percutaneous coronary intervention.
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The initial simplicity and associated low morbidity of
PCI as compared to surgical therapy is always attractive, but
the patient and family must understand the limitations
inherent in current PCI procedures, including a realistic
presentation of the likelihood of restenosis and the potential
for incomplete revascularization as compared with CABG
surgery. In patients with CAD who are asymptomatic or
have only mild symptoms, the potential benefit of antian-
ginal drug therapy along with an aggressive program of risk
reduction must also be understood by the patient before a
revascularization procedure is performed.
A. Asymptomatic or Mild Angina
In the previous ACC/AHA Guidelines for PTCA, spe-
cific recommendations were made separately for patients
with single- or multivessel disease. The current techniques
of PCI have matured to the point where, in patients with
favorable anatomy, the competent practitioner can perform
either single- or multivessel PCI at low risk and with a high
likelihood of initial success. For this reason, in this revision
of the Guidelines, recommendations will be made largely
based upon the patients’ clinical condition, specific coronary
lesion morphology and anatomy, LV function, and associ-
ated medical conditions, and less emphasis will be placed on
the number of lesions or vessels requiring PCI. The CCS
Class of angina (I to IV) is used to define the severity of
symptoms. The categories described in this section refer to
an initial PCI procedure in a patient without prior CABG
surgery.
The Committee recognizes that the majority of patients
with asymptomatic ischemia or mild angina should be
treated medically. The published ACIP study casts some
doubt on the wisdom of medical management for those
higher-risk patients who are asymptomatic or have mild
angina, but have objective evidence by both treadmill testing
and ambulatory monitoring of significant myocardial isch-
emia and CAD. In addition, there is a substantial portion of
the middle and older age populations in this country that
remains physically active, participating in sports, such as
tennis and skiing, or performing regular and vigorous
physical exercise, such as jogging, who have CAD. For such
individuals with moderate or severe ischemia and few
symptoms, revascularization with PCI or CABG surgery
may reduce their risk of serious or fatal cardiac events. For
this reason, patients in this category of higher-risk asymp-
tomatic ischemia or mild symptoms and severe anatomic
CAD are placed in Class I or II. PCI may be considered if
there is a high likelihood of success and a low risk of
morbidity or mortality. The judgment of the experienced
physician is deemed valuable in assessing the extent of
ischemia.
Recommendations for PCI in Asymptomatic or Class I
Angina Patients
Class I
1. Patients who do not have treated diabetes with
asymptomatic ischemia or mild angina with 1 or
more significant lesions in 1 or 2 coronary arteries
suitable for PCI with a high likelihood of success
and a low risk of morbidity and mortality. The vessels
to be dilated must subtend a large area of viable
myocardium (Table 12). (Level of Evidence: B)
Class IIa
1. The same clinical and anatomic requirements for
Class I, except the myocardial area at risk is of
moderate size or the patient has treated diabetes.
(Level of Evidence: B)
Table 11. Recommendations For PCI With and Without On-Site Cardiac Surgery
With On-Site Cardiac Surgery Without On-Site Cardiac Surgery
Elective PCI Class I Class III
Patients undergoing elective PCI in facilities with on-site
cardiac surgery.
Patients undergoing elective PCI in facilities without on-site cardiac
surgery.
(Level of Evidence: B) (Level of Evidence: C)
Primary PCI Class I Class IIb
Patients undergoing primary PCI in facilities with on-
site cardiac surgery.
(Level of Evidence: B)
Patients undergoing primary PCI in facilities without on-site cardiac
surgery, but with a proven plan for rapid access (within 1 h) to a cardiac
surgery operating room in a nearby facility with appropriate
hemodynamic support capability for transfer. The procedure should be
limited to patients with ST-segment elevation MI or new LBBB on
ECG, and done in a timely fashion (balloon inflation within
90 6 30 min of admission) by persons skilled in the procedure ($75
PCIs/year) and only at facilities performing a minimum of 36 primary
PCI procedures per year.
(Level of Evidence: B)
Class III
Patients undergoing primary PCI in facilities without on-site cardiac
surgery and without a proven plan for rapid access (within 1 h) to a
cardiac surgery operating room in a nearby facility with appropriate
hemodynamic support capability for transfer.
(Level of Evidence: C)
ECG 5 electrocardiography; LBBB 5 left bundle-branch block; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
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Class IIb
1. Patients with asymptomatic ischemia or mild an-
gina with >3 coronary arteries suitable for PCI
with a high likelihood of success and a low risk of
morbidity and mortality. The vessels to be dilated
must subtend at least a moderate area of viable
myocardium. In the physician’s judgment, there
should be evidence of myocardial ischemia by ECG
exercise testing, stress nuclear imaging, stress echo-
cardiography or ambulatory ECG monitoring, or
intracoronary physiologic measurements. (Level of
Evidence: B)
Class III
1. Patients with asymptomatic ischemia or mild an-
gina who do not meet the criteria as listed under
Class I or Class II and who have:
a. Only a small area of viable myocardium at
risk.
b. No objective evidence of ischemia.
c. Lesions that have a low likelihood of suc-
cessful dilation.
d. Mild symptoms that are unlikely to be due
to myocardial ischemia.
e. Factors associated with increased risk of
morbidity or mortality.
f. Left main disease.
g. Insignificant disease <50%. (Level of Ev-
idence: C)
B. Angina Class II to IV or Unstable Angina
Many patients with moderate or severe stable angina or
unstable angina do not respond adequately to medical
therapy and often have significant coronary artery stenoses
that are suitable for revascularization with CABG surgery or
PCI. In addition, a proportion of these patients have
reduced LV systolic function which places them in a group
that is known to have improved survival with CABG
surgery and possibly with revascularization by PCI. In
nondiabetic patients with 1- or 2-vessel disease in whom
angioplasty of 1 or more lesions has a high likelihood of
initial success, PCI is the preferred approach. In a minority
of such patients, CABG surgery may be preferred, particu-
larly for those in whom the left anterior descending coro-
nary artery can be revascularized with the internal mammary
artery or in those with left main coronary disease. In patients
with unstable angina or non–Q-wave MI, intensive medical
therapy should be initiated prior to revascularization with
PCI or CABG surgery. Patients with unstable angina and
non–ST-segment elevation MI have been randomized to
medical therapy or PCI in the FRISC II and TACTICS
TIMI 18 trials. These trials utilizing stenting as the primary
therapy have favored the invasive approach.
The indications for coronary angiography are summa-
rized in the ACC/AHA Coronary Angiography Guidelines
and recommendations for PCI are summarized in the
ACC/AHA Unstable Angina Guidelines. Indications for
PCI for patients with angina Class II to IV, unstable angina,
or non–Q-wave infarction follow.
Recommendations for Patients With Moderate or
Severe Symptoms (Angina Class II to IV, Unstable
Angina or Non–ST-Elevation MI) With Single- or
Multivessel Coronary Disease on Medical Therapy
Class I
1. Patients with 1 or more significant lesions in 1 or
more coronary arteries suitable for PCI with a high
likelihood of success and low risk of morbidity or
mortality (Table 5). The vessel(s) to be dilated must
subtend a moderate or large area of viable myocar-
dium and have high risk (Table 12). (Level of
Evidence: B)
Class IIa
1. Patients with focal saphenous vein graft lesions or
multiple stenoses who are poor candidates for re-
operative surgery. (Level of Evidence: C)
Class IIb
1. Patient has 1 or more lesions to be dilated with
reduced likelihood of success (Table 5) or the
vessel(s) subtend a less than moderate area of viable
myocardium. Patients with 2- or 3-vessel disease,
with significant proximal LAD CAD and treated
diabetes or abnormal LV function. (Level of Evi-
dence: B)
Class III
1. Patient has no evidence of myocardial injury or
ischemia on objective testing and has not had a trial
of medical therapy, or has:
a. Only a small area of myocardium at risk.
b. All lesions or the culprit lesion to be
dilated with morphology with a low like-
lihood of success.
c. A high risk of procedure-related morbidity
or mortality. (Level of Evidence: C)
2. Patients with insignificant coronary stenosis (e.g.,
<50% diameter). (Level of Evidence: C)
Table 12. Noninvasive Risk Stratification: High Risk (.3%
Annual Mortality Rate)
c High-risk treadmill score (score #-11)
c Stress-induced large perfusion defect (particularly if anterior)
c Stress-induced perfusion defects of moderate size
c Stress-induced multiple perfusion defect with LV dilation or increased
lung uptake (thallium-201)
c Echocardiographic wall motion abnormality (involving .2 segments)
developing at a low dose of dobutamine (#10 mgzkg21zmin21) or at a
low heart rate (120 bpm)
c Stress echocardiographic evidence of extensive ischemia
Adapted with permission from Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/
ACP-ASIM guidelines for the management of patients with chronic stable angina.
J Am Coll Cardiol 1999;33:2092–197.
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3. Patients with significant left main CAD who are
candidates for CABG. (Level of Evidence: B)
It is recognized by the Committee that the assessment of
risk of unsuccessful PCI or serious morbidity or mortality
must always be made with consideration of the alternative
therapies available for the patient, including more intensive
or prolonged medical therapy or surgical revascularization
(Table 13), especially in patients with unstable angina
pectoris.
When CABG surgery is a poor option because of high
risk due to special considerations or other organ system
disease, patients otherwise in Class IIb may be appropriately
managed with PCI. Under these special circumstances
formal surgical consultation is recommended.
C. Myocardial Infarction
The results of randomized clinical trials of intravenous
thrombolysis and subsequent management strategies of
immediate, delayed, and deferred PCI have established the
benefits of early pharmacologic and mechanical reperfusion
therapies for patients with acute MI.
Percutaneous coronary intervention is a very effective
method for re-establishing coronary perfusion and is suit-
able for $90% of patients. Considerable data support the
use of PCI for patients with acute MI. Reported rates of
achieving TIMI 3 flow, the goal of reperfusion therapy,
range from 70 to 90%. Late follow-up angiography dem-
onstrates that 87% of infarct arteries remain patent. Al-
though most evaluations of PCI have been in patients who
are eligible to receive thrombolytic therapy, considerable
experience supports the value of PCI for patients who may
not be suitable for thrombolytic therapy due to an increased
risk of bleeding.
Intracoronary stents appear to augment the results of PCI
for MI (Table 14). Preliminary results suggest that stenting
achieves a better immediate angiographic result with a larger
arterial lumen, less reclosure of the infarct-related artery,
and fewer subsequent ischemic events than PTCA alone.
Results from a randomized clinical trial suggest that stent-
ing enhances late clinical outcomes (reduction in composite
end point attributable to a decrease in target-vessel revas-
cularization) when compared to PTCA alone. However an
increase in mortality at 1 year among the stent group has
been reported in the Stent-PAMI trial.
Primary PTCA performed without routine stenting has
been compared to thrombolytic therapy in several random-
ized clinical trials. These investigations consistently dem-
onstrate that PTCA-treated patients experience less recur-
rent ischemia or infarction than those treated by
thrombolysis. Trends favoring a survival benefit with PTCA
are noted. Two meta-analyses showed superiority of PCI
over thrombolysis for mortality with risk reductions of 0.34
and 0.56. It is important to note that these results of PCI
have been achieved in medical centers with experienced Ta
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providers and under circumstances where angioplasty can be
performed immediately following patient presentation.
1. PCI in Thrombolytic-Ineligible Patients. Random-
ized, controlled clinical trials evaluating the outcome of PCI
for patients who present with ST-segment elevation but
who are ineligible for thrombolytic therapy and for patients
who experience infarction without ST-segment elevation
have not been performed. Nevertheless, there is a general
consensus that PCI is an appropriate means for achieving
reperfusion in patients who cannot receive thrombolytics
because of increased risk of hemorrhage. Other reasons also
exclude acute MI patients from thrombolytic therapy and
the outcome of PCI in these patients may differ from those
eligible for lytic therapy. For example, patients who present
without ST-elevation are more often older and female and
have higher in-hospital mortality than those with ST-
segment elevation. Little data are available to characterize
the value of primary PCI for this subset of acute MI patients
(Table 15).
2. Post-Thrombolysis PCI. In asymptomatic patients, the
strategies of routine PCI of the stenotic infarct-related
artery immediately after successful thrombolysis show no
benefit with regard to salvage of jeopardized myocardium or
prevention of reinfarction or death. In some studies this
approach was associated with increased incidence of adverse
events, which include bleeding, recurrent ischemia, emer-
gency coronary artery surgery, and death. Routine PCI
immediately after thrombolysis may increase the chance forTa
bl
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Table 15. Contraindications and Cautions for Thrombolytic Use
in Myocardial Infarction*
Contraindications
c Previous hemorrhagic stroke at any time, other strokes or
cerebrovascular events within 1 year
c Known intracranial neoplasm
c Active internal bleeding (does not include menses)
c Suspected aortic dissection
Caution/relative contraindications
c Severe uncontrolled hypertension on presentation (blood pressure
.180/110 mm Hg)†
c History of prior cerebrovascular accident or known intracerebral
pathology not covered in contraindications
c Current use of anticoagulants in therapeutic doses (INR $2–3);
known bleeding diathesis
c Recent trauma (within 2–4 weeks) including head trauma or traumatic
or prolonged (.10 min) CPR or major surgery (3 weeks)
c Noncompressible vascular punctures
c Recent (within 2 to 4 weeks) internal bleeding
c For streptokinase/anistreplase: prior exposure (especially within 5 days–
2 years) or prior allergic reaction
c Pregnancy
c Active peptic ulcer
c History of chronic severe hypertension
*Viewed as advisory for clinical decision making and may not be all-inclusive or
definitive; †Could be an absolute contraindication in low-risk patients with myocar-
dial infarction.
INR 5 International Normalized Ratio; CPR 5 cardiopulmonary resuscitation.
Reproduced with permission from Ryan TJ, Antman EM, Brooks NH, et al.
ACC/AHA guidelines for the management of patients with acute myocardial
infarction: a report of the American College of Cardiology/American Heart Associ-
ation Task Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). J Am Coll Cardiol 1999;34:890–911.
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vascular complications at the catheterization access site and
hemorrhage into the infarct-related vessel wall.
3. Rescue PCI. Rescue (also known as salvage) PCI is
defined as PCI after failed thrombolysis for patients with
continuing or recurrent myocardial ischemia. Rescue PCI
has resulted in higher rates of early infarct-artery patency,
improved regional infarct zone wall motion, and greater
freedom from adverse in-hospital clinical events compared
to a deferred PCI strategy. The randomized evaluation of
rescue PCI with combined utilization end points trial
(RESCUE) demonstrated a reduction in rates of in-hospital
death and combined death and congestive heart failure
maintained up to 1 year after study entry for patients
presenting with anterior wall MI who failed thrombolytic
therapy. Improvement in TIMI grade flow from #2 to 3
may offer additional clinical benefit.
4. PCI for Cardiogenic Shock. Observational studies
support the value of PCI for patients who develop cardio-
genic shock in the early hours of MI. For patients who do
not have mechanical causes of shock, such as acute mitral
regurgitation or septal or free wall rupture, mortality among
those having PCI is lower than those treated by medical
means.
A randomized clinical trial has further clarified the role of
emergency revascularization (ERV) in acute MI compli-
cated by cardiogenic shock. This multicenter trial supports
the use of ERV with PCI in appropriate candidates for
patients ,75 years old with acute MI complicated by
cardiogenic shock. After 6 months, there was significant
survival benefit to early revascularization. These data
strongly support the approach that patients ,75 years with
acute MI complicated by cardiogenic shock should undergo
emergency revascularization and support measures.
5. PCI Hours to Days After Thrombolysis. Patients who
achieve reperfusion and myocardial salvage following
thrombolytic therapy may experience reocclusion of the
infarct artery and recurrent MI. This concern has prompted
the routine use of catheterization and PCI prior to hospital
discharge to identify and dilate the culprit lesion. The
SWIFT study examined 800 patients with acute MI ran-
domly assigned to PCI within 2 to 7 days after thrombolysis
or to conservative management with intervention for spon-
taneous or provocable ischemia. There were no differences
in the two treatment strategies regarding LV function,
incidence of reinfarction, in-hospital survival, or 1-year
survival rate. These data indicate that routine PCI of the
infarct-related artery in the absence of spontaneous or
provoked ischemia is not warranted.
Initial studies of late (.6 to 12 h) PCI in asymptomatic
survivors of MI indicate that opening an occluded artery
does not appear to alter the process of LV dilation, the
incidence of spontaneous and inducible arrhythmias, or
prognosis. Although data supporting the argument to open
occluded infarct-related arteries are persuasive, at least for
large arteries subtending large areas of myocardium, there
are few randomized trials supporting this approach. It
should be noted that the overwhelming majority of trials
were performed prior to the widespread use of stents and
platelet IIb/IIIa receptor blockade and thus, the potential
impact and benefit of these newer therapies in this clinical
setting needs re-evaluation.
6. PCI After Thrombolysis in Selected Patient Sub-
groups. a. YOUNG AND ELDERLY POST-INFARCT PA-
TIENTS. Although not supported by randomized trials,
routine cardiac catheterization following thrombolytic ther-
apy for AMI has been a frequently performed strategy in all
age groups. Young (,50 years) patients often undergo
cardiac catheterization after thrombolytic therapy due to a
“perceived need” to define coronary anatomy and thus
establish psychological as well as clinical outcomes. In
contrast, older (.75 years) patients have higher in-hospital
and long-term mortality rates and enhanced clinical out-
comes when treated with primary PCI. Confirmatory stud-
ies to determine quality-of-life aspects of care in younger
patients and to define the potential of other modes of
coronary revascularization in older patient groups are not yet
available. Based on the current data, with the exception of
patients presenting with cardiogenic shock, PCI should be
based on clinical need without special consideration of age.
b. PATIENTS WITH PRIOR MYOCARDIAL INFARCTION.
A prior MI is an independent predictor of death, reinfarc-
tion, and need for urgent coronary bypass surgery. In the
TIMI-II study, patients with a history of prior MI had a
higher 42-day mortality (8.8% vs. 4.3%; p , 0.001), higher
prevalence of multivessel CAD (60% vs. 28%; p , 0.001),
and a lower LV ejection fraction (42% vs. 48%; p , 0.001)
compared to patients with a first MI. Mortality tended to be
lower among patients with a prior MI undergoing the
invasive compared to the conservative strategy, a benefit
which persisted up to 1 year following study entry.
Based on the earlier findings in this document and
current practice, PCI should be based on clinical need. The
presence of prior MI places the patient in a higher risk
subset and should be considered in the PCI decision.
Recommendations for Primary PCI for Acute
Transmural MI Patients as an Alternative to
Thrombolysis
Class I
1. As an alternative to thrombolytic therapy in pa-
tients with AMI and ST-segment elevation or new
or presumed new left bundle branch block who can
undergo angioplasty of the infarct artery <12 h
from the onset of ischemic symptoms or >12 h if
symptoms persist, if performed in a timely fashion*
by individuals skilled in the procedure† and sup-
ported by experienced personnel in an appropriate
laboratory environment.‡ (Level of Evidence: A)
2. In patients who are within 36 h of an acute ST
elevation/Q-wave or new left bundle branch block
MI who develop cardiogenic shock, are <75 years
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of age, and revascularization can be performed
within 18 h of the onset of shock by individuals
skilled in the procedure† and supported by experi-
enced personnel in an appropriate laboratory envi-
ronment.‡ (Level of Evidence: A)
Class IIa
1. As a reperfusion strategy in candidates who have a
contraindication to thrombolytic therapy. (Level of
Evidence: C)
Class III
1. Elective PCI of a non–infarct-related artery at the
time of acute MI. (Level of Evidence: C)
2. In patients with acute MI who:
a. have received fibrinolytic therapy within
12 h and have no symptoms of myocardial
ischemia.
b. are eligible for thrombolytic therapy and
are undergoing primary angioplasty by an
inexperienced operator (individual who
performs <75 PCI procedures/year).
c. are beyond 12 h after onset of symptoms
and have no evidence of myocardial isch-
emia. (Level of Evidence: C)
Recommendations for PCI After Thrombolysis
Class I
1. Objective evidence for recurrent infarction or isch-
emia (rescue PCI). (Level of Evidence: B)
Class IIa
1. Cardiogenic shock or hemodynamic instability.
(Level of Evidence: B)
Class IIb
1. Recurrent angina without objective evidence of
ischemia/infarction. (Level of Evidence: C)
2. Angioplasty of the infarct-related artery stenosis
within hours to days (48 h) following successful
thrombolytic therapy in asymptomatic patients
without clinical and/or inducible evidence of isch-
emia. (Level of Evidence: B)
Class III
1. Routine PCI within 48 h following failed throm-
bolysis. (Level of Evidence: B)
2. Routine PCI of the infarct-artery stenosis immedi-
ately after thrombolytic therapy. (Level of Evidence: A)
Recommendations for PCI During Subsequent
Hospital Management After Acute Therapy for AMI
Including Primary PCI
Class I
1. Spontaneous or provocable myocardial ischemia dur-
ing recovery from infarction. (Level of Evidence: C)
2. Persistent hemodynamic instability. (Level of Evi-
dence: C)
Class IIa
1. Patients with LV ejection fraction <0.4, CHF, or
serious ventricular arrhythmias. (Level of Evidence: C)
Class IIb
1. Coronary angiography and angioplasty for an oc-
cluded infarct-related artery in an otherwise stable
patient to revascularize that artery (open artery
hypothesis). (Level of Evidence: C)
2. All patients after a non–Q-wave MI. (Level of
Evidence: C)
3. Clinical HF during the acute episode, but subse-
quent demonstration of preserved LV function (LV
ejection fraction >0.4). (Level of Evidence: C)
Class III
1. PCI of the infarct-related artery within 48 to 72 h
after thrombolytic therapy without evidence of
spontaneous or provocable ischemia. (Level of Ev-
idence: C)
D. Percutaneous Intervention in Patients With Prior
Coronary Bypass Surgery
Ischemic symptoms recur in 4% to 8% of patients/year
following CABG. Recurrence of symptoms can be attrib-
uted to progression of native vessel coronary disease (5%/
year) and bypass conduit occlusion, particularly SVG failure
(7% in week 1; 15 to 20% in first year; 1 to 2%/year during
the first 5 to 6 years and 3 to 5%/year in years 6 to 10
postoperatively). At 10 years postoperatively, approximately
half of all SVG conduits are occluded and only half of the
remaining patent grafts are free of significant disease. The
requirement for repeat revascularization procedures in-
creases over time from the initial revascularization, partic-
ularly in younger patients. Although arterial conduits ex-
hibit improved long-term patency, stenosis or occlusion of
these grafts can occur. Thus, patients with recurrent isch-
emic symptoms following CABG may require repeat revas-
cularization due to diverse anatomic problems.
Risk of repeat surgical revascularization is higher (hospi-
tal mortality 7 to 10%) than initial CABG and both
long-term relief of angina and bypass graft patency are lower
than that of the first procedure. In addition, patients with
prior bypass surgery may have limited graft conduits, im-
paired LV function, advanced age, and coexisting medical
conditions (cerebrovascular disease; renal and pulmonary
insufficiency) which may complicate repeat surgical coronary
revascularization and prompt consideration for catheter-
based intervention.
1. Early Ischemia After CABG. Recurrent ischemia early
(,30 days) postoperatively usually reflects graft failure,
often secondary to thrombosis, and may occur in both
saphenous vein and arterial graft conduits. Incomplete
revascularization and unbypassed native vessel stenoses or
*Performance standard: balloon inflation within 90 (630) min of hospital admis-
sion; †Individuals who perform $75 PCI procedures/year; ‡Centers that perform
.200 PCI procedures/year and have cardiac surgical capability.
2232 Smith et al. JACC Vol. 37, No. 8, 2001
ACC/AHA Percutaneous Coronary Intervention Guidelines June 15, 2001:2215–38
stenoses distal to a bypass graft anastomosis may also
precipitate recurrent ischemia. Urgent coronary angiogra-
phy is indicated to define the anatomic cause of ischemia
and to determine the best course of therapy. Emergency
PCI of a focal graft stenosis (venous or arterial) or recana-
lization of an acute graft thrombosis may successfully relieve
ischemia in the majority of patients. Balloon dilation across
suture lines has been accomplished safely within days of
surgery. Adjunctive therapy with abciximab for percutane-
ous intervention during the first week following bypass
surgery has been limited but intuitively may pose less risk for
hemorrhage than fibrinolysis. As flow in vein graft conduits
is pressure dependent, intra-aortic balloon pump support
should be considered in the context of systemic hypotension
and/or severe LV dysfunction. If feasible, PCI of both
bypass graft and native vessel offending stenoses should be
attempted, particularly if intracoronary stents can be suc-
cessfully deployed.
When ischemia occurs 1 to 12 months following surgery,
the etiology is usually peri-anastomotic graft stenosis. Distal
anastomotic stenoses (both arterial and venous) respond
well to balloon dilation alone and have a more favorable
long-term prognosis than stenoses involving the mid-shaft
or proximal vein graft anastomosis. The immediate results
of PCI in mid-shaft ostial or distal anastomotic vein graft
stenoses may be enhanced by coronary stent deployment.
Percutaneous transluminal coronary angioplasty with or
without stent deployment can be successfully performed in
patients with distal anastomotic stenoses involving the
gastroepiploic artery bypass graft and in patients with free
radial artery bypass grafts as well. Percutaneous intervention
has also been effective in relieving ischemia for patients with
the stenosis of the subclavian artery proximal to the origin of
a patent left internal mammary artery bypass graft.
2. Late Ischemia After CABG. Ischemia occurring more
than 1 year postoperatively usually reflects the development
of new stenoses in graft conduits and/or native vessels that
may be amenable to PCI. Slow-flow occurs more frequently
in grafts having diffuse atherosclerotic involvement, angio-
graphically demonstrable thrombus, irregular or ulcerative
lesion surfaces, and with long lesions having large plaque
volume.
Final patency after PTCA is greater for distal SVG
lesions than for ostial or mid-SVG lesions, and stenosis
location appears to be a better determinant of final patency
than graft age or the type of interventional device used.
Percutaneous intervention for chronic vein graft occlusion
has been problematic. Percutaneous transluminal coronary
angioplasty alone has been associated with high complica-
tion rates and low rates of sustained patency. Favorable
results have been obtained with both local “targeted” and
more prolonged infusion of fibrinolytic agents for nonoc-
clusive intragraft thrombus. Thrombolytic catheter-based
systems appear to successfully treat SVG thrombosis as well
as or better than thrombolytic agents.
3. Early and Late Outcomes of Percutaneous Interven-
tion. Patients with prior bypass surgery who undergo suc-
cessful PCI have a long-term outcome that is dependent on
patient age, the degree of LV dysfunction, and the presence
of multivessel coronary atherosclerosis. The best long-term
results are observed after recanalization of distal anastomotic
stenoses occurring within 1 year of operation. Conversely,
event-free survival is less favorable following angioplasty of
totally occluded SVGs, ostial vein graft stenoses, or grafts
with diffuse or multicentric disease. Coexistent multisystems
disease, the presence of which may have prompted the
choice of a percutaneous revascularization strategy, may also
influence long-term outcomes in this population.
4. Surgery Versus Percutaneous Reintervention. Aged,
diffuse, friable and degenerative SVG disease in the absence
of a patent arterial conduit to the left anterior descending
artery represents a prime consideration for repeat surgical
revascularization. The overall risk of repeat operation, es-
pecially the presence of comorbidities such as concomitant
cerebrovascular, renal, or pulmonary disease and the poten-
tial for jeopardizing patent, nondiseased bypass conduits
must be carefully considered. Isolated, friable stenoses in
vein grafts may be approached with primary stenting or the
combination of extraction atherectomy and stenting in an
attempt to reduce the likelihood of distal embolization.
In general, patients with multivessel disease, failure of
multiple SVGs, and moderately impaired LV function,
derive the greatest benefit from the durability provided by
surgical revascularization with arterial conduits. Regardless
of repeat revascularization strategy, risk-factor modification
with cessation of smoking and lipid-lowering therapy
should be implemented in patients with prior CABG
surgery. An aggressive lipid-lowering strategy that targets a
low-density lipoprotein level of less than 90 mg/L can be
effective in reducing recurrent ischemic events and the need
for subsequent revascularization procedures.
Recommendations for PCI With Prior CABG
Class I
1. Patients with early ischemia (usually within 30
days) after CABG. (Level of Evidence: B)
Class IIa
1. Patients with ischemia occurring 1 to 3 years post-
operatively and preserved LV function with discrete
lesions in graft conduits. (Level of Evidence: B)
2. Disabling angina secondary to new disease in a
native coronary circulation. (If angina is not typical,
the objective evidence of ischemia should be ob-
tained.) (Level of Evidence: B)
3. Patients with diseased vein grafts >3 years follow-
ing CABG. (Level of Evidence: B)
Class III
1. PCI to chronic total vein graft occlusions. (Level of
Evidence: B)
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2. Patients with multivessel disease, failure or multi-
ple SVGs, and impaired LV function. (Level of
Evidence: B)
E. Use of Adjunctive Technology (Intracoronary
Ultrasound Imaging, Flow Velocity, and Pressure)
The limitations of coronary angiography for diagnostic
and interventional procedures can be reduced by employing
adjunctive technology of intracoronary ultrasound imaging,
flow velocity, and pressure. Information obtained from the
adjunctive modalities of intravascular imaging and physiol-
ogy can improve PCI methods and outcomes.
1. Intravascular Ultrasound Imaging (IVUS). IVUS is
not necessary for all stent procedures. The results of the
French Stent Registry study of 2900 patients treated with-
out coumadin and without IVUS reported a subacute
closure rate of 1.8%. In the STARS trial, a subacute closure
rate of 0.6% in patients having optimal stent implantation
supports the approach that IVUS does not appear to be
required routinely in all stent implantations. However, the
use of IVUS for evaluating results in high-risk procedures
(i.e., those patients with multiple stents, impaired TIMI
grade flow or coronary flow reserve, and marginal angio-
graphic appearance) appears warranted.
In the context of published data and growing clinical
experience, the Writing Committee has modified prior
recommendations for the use of IVUS as follows.
Recommendations for Coronary Intravascular
Ultrasound
Class IIa
1. Assessment of the adequacy of deployment of cor-
onary stents, including the extent of stent apposi-
tion and determination of the minimum luminal
diameter within the stent. (Level of Evidence: B)
2. Determination of the mechanism of stent restenosis
(inadequate expansion vs. neointimal proliferation)
and to enable selection of appropriate therapy
(plaque ablation vs. repeat balloon expansion).
(Level of Evidence: B)
3. Evaluation of coronary obstruction at a location
difficult to image by angiography in a patient with
a suspected flow-limiting stenosis. (Level of Ev-
idence: C)
4. Assessment of a suboptimal angiographic result
following PCI. (Level of Evidence: C)
5. Diagnosis and management of coronary disease
following cardiac transplantation. (Level of Evi-
dence: C)
6. Establish presence and distribution of coronary
calcium in patients for whom adjunctive rotational
atherectomy is contemplated. (Level of Evidence: C)
7. Determination of plaque location and circumferen-
tial distribution for guidance of directional coro-
nary atherectomy. (Level of Evidence: B)
Class IIb
1. Determine extent of atherosclerosis in patients with
characteristic anginal symptoms and a positive
functional study with no focal stenoses or mild
CAD on angiography. (Level of Evidence: C)
2. Preinterventional assessment of lesional character-
istics and vessel dimensions as a means to select
an optimal revascularization device. (Level of
Evidence: C)
Class III
1. When angiographic diagnosis is clear and no inter-
ventional treatment is planned. (Level of Evidence: C)
2. Coronary Flow Velocity and Coronary Vasodilatory
Reserve. Coronary flow velocity reserve (CVR), the ratio of
hyperemic to basal flow, reflects flow resistance through the
epicardial artery and the corresponding myocardial bed. For
lesion assessment, a normal CVR indicates a nonphysiologi-
cally significant stenosis. An abnormal CVR indicates that
the stenosis in the epicardial artery is significant when the
microcirculation is normal, confirmed by measuring rCVR.
Several studies report that deferring PCI of non–flow-
limiting lesions is safe, with ,10% rate of lesion progres-
sion.
3. Coronary Artery Pressure and Fractional Flow Re-
serve. Fractional flow reserve (FFR) of the myocardium is
the ratio of distal coronary pressure to aortic pressure
measured during maximal hyperemia, which represents the
fraction of normal blood flow through the stenotic artery.
The normal FFR value for all vessels under all hemody-
namic conditions, regardless of the status of microcircula-
tion is 1.0. FFR values ,0.75 are associated with abnormal
stress tests. FFR does not use measurements in a reference
vessel and is thought to be epicardial lesion-specific.
Reports indicate that a physiologic assessment can deter-
mine whether PTCA alone has achieved a satisfactory result
with 6-month outcome equivalent to that reported with
elective stenting. The DEBATE trial in 224 patients found
that when a final diameter stenosis ,35% and an excellent
physiologic result (CVR .2.5) were obtained after PTCA
(44/224 patients), the intermediate-term (6 months) target
lesion revascularization and angiographic restenosis rates
were 16%. Similar data have been reported for FFR. The
application of coronary physiologic adjunctive modalities
can facilitate decision making for moderate lesions, the
appropriateness of PTCA, and the use of provisional stent-
ing.
Recommendations for Intracoronary Physiologic
Measurements (Doppler Ultrasound, FFR)
Class IIa
1. Assessment of the physiological effects of interme-
diate coronary stenoses (30 to 70% luminal narrow-
ing) in patients with anginal symptoms. Coronary
pressure or Doppler velocimetry may also be useful
as an alternative to performing noninvasive func-
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tional testing (e.g., when the functional study is
absent or ambiguous) to determine whether an
intervention is warranted. (Level of Evidence: B)
Class IIb
1. Evaluation of the success of percutaneous coronary
revascularization in restoring flow reserve and to
predict the risk of restenosis. (Level of Evidence: C)
2. Evaluation of patients with anginal symptoms with-
out an apparent angiographic culprit lesion. (Level
of Evidence: C)
Class III
1. Routine assessment of the severity of angiographic
disease in patients with a positive, unequivocal
noninvasive functional study. (Level of Evidence: C)
VI. MANAGEMENT OF PATIENTS UNDERGOING PCI
A. Experience With New Technologies
The introduction of coronary stents and atherectomy
devices has broadened the scope of patients that can be
approached by PCI beyond those that could be safely
treated by PTCA alone.
1. Acute Results. Significant reduction in the acute com-
plication rate for PTCA has resulted from the adjunctive
use of GP receptor IIb/IIIa blockers, which have been
shown to reduce abrupt closure and periprocedural MI rates
compared to placebo. Improved acute outcomes (in terms of
abrupt closure rates and reduced target lesion residual
diameter stenosis) have also been seen with the use of
coronary stents, DCA, and adjunctive rotational atherec-
tomy.
2. Late-Term Results. PCI devices offer the possibility of
lower restenosis compared to PTCA in the native coronary
circulation. Lower restenosis rates have been demonstrated
for balloon-expandable slotted tubular stents in large
($3 mm) native coronary arteries but are variable depending
on lesion length for SVG lesions. Initial trials of DCA
showed no benefit compared to PTCA for elective single-
lesion treatment. Despite the improvement in acute results
seen for rotational atherectomy and excimer laser, there is
no evidence that these devices improve the late outcomes in
lesions than can be feasibly treated by PTCA or stenting
alone.
B. Antiplatelet and Antithrombotic Therapies and
Coronary Angioplasty
1. Aspirin, Ticlopidine, Clopidogrel. Aspirin reduces the
frequency of ischemic complications after coronary angio-
plasty. Although the minimum effective aspirin dosage in
the setting of coronary angioplasty has not been established,
an empiric dose of aspirin, 80 to 325 mg, given at least 2 h
before PCI is generally recommended. While other anti-
platelet agents have similar antiplatelet effects to aspirin,
only the thienopyridine derivatives, ticlopidine and clopi-
dogrel, have been routinely used as alternative antiplatelet
agents in aspirin-sensitive patients during coronary angio-
plasty.
Ticlopidine has a number of important side effects. The
most severe side effect is severe neutropenia, occurring in
approximately 1% of patients. Clopidogrel, 300 mg loading
dose followed by 75 mg daily, may be used as an alternative
to ticlopidine in patients undergoing stent placement. A
number of nonrandomized trials and a randomized trial
have failed to show a difference in the clinical outcomes
among patients treated with ticlopidine and clopidogrel
after stent placement. A small number of cases of throm-
bocytopenia purpura have been reported in patients treated
with clopidogrel; therefore, patients should be monitored
during treatment for occurrence of this untoward effect.
2. GP IIb/IIIa Inhibitors. The binding of fibrinogen and
other adhesive proteins to adjacent platelets by means of the
GP IIb/IIIa receptor serves as the “final common pathway”
of platelet-thrombus formation and can be effectively atten-
uated by GP IIb/IIIa antagonists. These agents have re-
duced the frequency of ischemic complications after coro-
nary angioplasty.
Based on the numerous trials to date (Fig. 1), intravenous
GP IIb/IIIa receptor inhibitors should be considered in
patients undergoing coronary angioplasty, particularly those
with unstable angina or with other clinical characteristics of
high-risk. There is no consistent evidence that the GP
IIb/IIIa inhibitors reduce the frequency of late restenosis in
the nondiabetic patient. In EPISTENT, diabetic patients
who received abciximab therapy in conjunction with stent
deployment had a 51% reduction in target-vessel revascu-
larization at 6 months. This trial is the only one that has
shown a reduction in target-vessel revascularization in the
diabetic group. It will be important to determine if support-
ing evidence is found from other trials using this agent and
other GP IIb/IIIa antagonists.
3. Heparin. Heparin is an important component for PCI,
despite dosing uncertainties and an unpredictable therapeu-
tic response with the unfractionated preparation. Higher
levels of anticoagulation with heparin are roughly correlated
with therapeutic efficacy in the reduction of complications
during coronary angioplasty, albeit at the expense of bleed-
ing complications at very high levels of heparin dosing. It
appears that weight-adjusted heparin dosing may provide a
clinically superior anticoagulation method over fixed hepa-
rin dosing, although definitive studies are lacking.
Some patients with unstable angina are treated with
low-molecular-weight heparin (LMWH) prior to coronary
angioplasty. Anticoagulation monitoring is not routinely
possible with LMWH, and conventional dosages of unfrac-
tionated heparin are currently recommended. Conventional
ACT monitoring methods may underestimate the true
degree of periprocedural anticoagulation with LMWH. Use
of LMWH as the sole anticoagulant during PCI is not
supported at this time in the absence of absolute or relative
contraindications to unfractionated heparin, although data
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from clinical trials of these agents administered alone or in
conjunction with GP IIb/IIIa blockade are forthcoming.
In those patients who do not receive GP IIb/IIIa inhib-
itors, sufficient unfractionated heparin should be given
during coronary angioplasty to achieve an ACT of 250 to
300 s with the HemoTec device and 300 to 350 s with the
Hemochron device.
The unfractionated heparin bolus should be reduced to 50
to 70 IU/kg when GP IIb/IIIa inhibitors are given in order
to achieve a target ACT of 200 s using either the HemoTec
or Hemochron device.
C. Post-PCI Management
Following PCI, in-hospital care should focus on moni-
toring the patient for recurrent myocardial ischemia, achiev-
ing hemostasis at the catheter insertion site, and detecting
and preventing contrast-induced renal failure. Attention
should also be directed toward implementing appropriate
secondary atherosclerosis prevention programs. The patient
should understand and adhere to recommended medical
therapies and behavior modifications known to reduce
subsequent morbidity and mortality from coronary heart
disease.
Most patients can be safely discharged from the hospital
within 24 h after an uncomplicated elective PCI. Special
skilled nursing units have been developed by many institu-
tions to facilitate post-PCI management. Specific protocols
for sheath removal, continuation of anticoagulation or anti-
platelet therapies, and observation for recurrent myocardial
ischemia/infarction and contrast-induced renal failure are of
particular assistance in ensuring appropriate outcomes during
this period. Pilot studies suggest that selected patients may be
discharged on the same day after PCI especially when the
procedure is performed by the percutaneous radial or brachial
approach. However, confirmation by larger studies is necessary
prior to widespread endorsement of this strategy.
1. Post-Procedure Evaluation of Ischemia. After PCI,
chest pain may occur in as many as 50% of patients. ECG
evidence of ischemia identifies those with significant risk for
acute vessel closure. When angina pectoris or ischemic
ECG changes occur after PCI, the decision to proceed with
further interventional procedures, CABG surgery, or med-
ical therapy should be individualized based on factors such
as hemodynamic stability, amount of myocardium at risk,
and the likelihood that the treatment will be successful.
Patients with renal dysfunction and diabetes should be
monitored for contrast-induced nephropathy. In addition,
those patients receiving higher contrast loads or a second
contrast load within 72 h should have renal function
assessed. Whenever possible, nephrotoxic drugs (certain
antibiotics, nonsteroidal anti-inflammatory agents, and cy-
closporine) and metformin (especially in those with pre-
existing renal dysfunction) should be withheld for 24 to 48 h
prior to performing PCI and for 48 h afterwards.
2. Risk-Factor Modifications. All patients should be in-
structed about necessary behavior and risk-factor modifica-
tion and the appropriate medical therapies for the secondary
prevention of atherosclerosis prior to leaving the hospital.
The interventional cardiologist should emphasize the im-
portance of these measures directly to the patient as failure
to do so may suggest that secondary prevention therapies are
not necessary. The interventional cardiologist should inter-
act with the primary care physician to assure that necessary
secondary prevention therapies are initiated and maintained.
Secondary prevention measures are an essential part of
long-term therapy because they can reduce future morbidity
and mortality associated with the atherosclerotic process.
Figure 1. Death or nonfatal MI outcomes at 30 days in 10 randomized, placebo-controlled trials of GP IIb/IIIa blockers. Data and acronyms from
references 30–39 (these numbers coincide with references in the original article). Risk ratio with 95% CI, size of RR box being proportional to total sample
size. Frequency of death or nonfatal MI in columns 4 and 5. Overall (all 10 trials) benefit of GP IIb/IIIa blockade highly significant (RR 5 0.79 [95%
CI 0.73–0.85; p , 1029). GP 5 glycoprotein; OR 5 odds ratio; CI 5 confidence interval; MI 5 myocardial infarction. Reproduced with permission from
Topol EJ, et al. Lancet 1999;353:227–31.
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Depending on the risk factors and contraindications
present, advice should include aspirin therapy, hypertensive
control, diabetic management, aggressive control of serum
lipids to a target LDL goal ,100 mgm/dl following AHA
guidelines, abstinence from tobacco use, weight control,
regular exercise, and ACE inhibitor therapy as recom-
mended in the AHA/ACC consensus statement on second-
ary prevention.
3. Exercise Testing After PCI. Although restenosis re-
mains the major limitation of PCI, symptom status is an
unreliable index to development of restenosis with 25% of
asymptomatic patients documented as having ischemia on
exercise testing.
Because myocardial ischemia, whether painful or silent,
worsens prognosis, some authorities have advocated routine
testing. However, the ACC/AHA practice guidelines for
exercise testing favor selective evaluation in patients consid-
ered to be at particularly high risk (e.g., patients with
decreased LV function, multivessel CAD, proximal left
anterior descending disease, previous sudden death, diabetes
mellitus, hazardous occupations, and suboptimal PCI re-
sults). The exercise ECG is an insensitive predictor of
restenosis, with sensitivities ranging from 40 to 55%, sig-
nificantly less than those obtainable with SPECT or exer-
cise echocardiography. This lower sensitivity of the exercise
ECG and its inability to localize disease limits its usefulness
in patient management both before and after PCI. For those
reasons, stress imaging is preferred to evaluate symptomatic
patients after PCI. If the patient’s exertional capacity is
significantly limited, coronary angiography may be more
expeditious to evaluate symptoms of typical angina. Exercise
testing after discharge is helpful for activity counseling
and/or exercise training as part of cardiac rehabilitation.
Neither exercise testing nor radionuclide imaging is indi-
cated for the routine, periodic monitoring of asymptomatic
patients after PCI without specific indications.
VII. SPECIAL CONSIDERATIONS
A. Ad-Hoc Angioplasty—PCI at the Time of Initial
Cardiac Catheterization
Ad-hoc coronary intervention is PCI performed at the
same time as diagnostic cardiac catheterization. Since the
last revision of these Guidelines, there has been an increase
in ad-hoc interventions with reported incidence ranging
from 52 to 83%.
Ad-hoc coronary intervention is particularly suitable for
patients with clinical evidence of restenosis 6 to 12 months
following the initial procedure, patients undergoing primary
angioplasty for MI, and patients with refractory unstable
angina in need of urgent revascularization. Ad-hoc PCI
should be performed only in a well-informed patient,
particularly in the setting of single-vessel disease without
morphologic features predictive of an adverse outcome,
when it is clear that this treatment strategy is the best
alternative. This committee endorses the recommendations
from the Society for Cardiac Angiography and Interven-
tions that ad-hoc PCI be individualized and not be a
standard or required strategy for all patients.
B. PCI in Cardiac Transplant Patients
Although high procedural success can be achieved and
PCI may be applied in a selected cardiac transplant popu-
lation with comparable success and complication rates to the
routine patient population, it remains unknown whether
PCI prolongs allograft survival. Coronary stenting in cardiac
allograft vascular disease has been performed in small
numbers of patients with favorable results. Long-term
survival effects remain under examination.
C. Management of Clinical Restenosis
Although atheroablation devices have been developed in
an attempt to lower the second restenosis risk in patients,
none has shown an incremental benefit over PTCA. It is
recommended that patients who develop restenosis follow-
ing an initially successful PTCA be considered for repeat
PCI with stent placement. Factors that may influence this
decision include the technical difficulty of the initial proce-
dure, the potential for the lesion to be treated successfully
with a stent, and the severity and extent of the restenotic
process. Each time restenosis recurs, consideration should
be given to alternate methods of revascularization, particu-
larly CABG surgery, as well as continued medical therapy.
D. Restenosis After Stent Implantation (In-stent Restenosis)
Intracoronary vascular radiation for in-stent restenosis
with either gamma or beta radiation is the most promising
therapy for in-stent restenosis at this time, reducing the
chance for repeat restenosis by other methods from 50 to
60% to 25 to 35%. In the absence of vascular radiation for
in-stent restenosis, there appears to be little difference in
outcome between angioplasty alone as compared to combi-
nation with ablative techniques.
E. Cost-Effectiveness Analysis for PCI
While there is no established cost-effectiveness ratio
threshold, cost-effectiveness ratios of ,$20,000 per QALY
(such as seen in the treatment of severe diastolic hyperten-
sion or cholesterol lowering in patients with ischemic heart
disease) are considered highly favorable and consistent with
well accepted therapies.
In patients with severe angina, normal LV function, and
single-vessel disease of the left anterior descending artery,
the cost-effectiveness ratio for PTCA, directional coronary
atherectomy, or coronary stenting that can be expected to
provide .90% success rate with ,3% major acute compli-
cation rate is very favorable (,$20,000 per QALY) com-
pared to medical therapy. In patients with 3-vessel coronary
disease who have comorbidities that increase operative risk
for CABG surgery, PCI that is felt to be safe and feasible is
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reasonably acceptable ($20,000 to $60,000 per QALY). In
patients in the post-MI setting, a strategy of routine,
nonsymptom-driven coronary, angiography and PCI per-
formed for critical (.70% diameter stenosis) culprit coro-
nary lesions amenable to PTCA or stenting has been
proposed to be reasonably cost-effective in many subgroups.
In patients with symptomatic angina or documented
ischemia and 3-vessel coronary disease, for which bypass
surgery can be expected to provide full revascularization and
an acute complication rate of less than 5%, the cost-
effectiveness of PCI is not well established. Although
PTCA for 2- and 3-vessel coronary disease appears to be as
safe, but initially less expensive, than CABG surgery, the
costs of PTCA converge towards the higher costs of bypass
surgery after 3 to 5 years. Thus, while PTCA or CABG
surgery has been shown to be cost-effective when compared
to medical therapy, there is no evidence for incremental
cost-effectiveness of PTCA over bypass surgery for 2- or
3-vessel coronary disease in patients who are considered
good candidates for both procedures. For patients with 1- or
2-vessel coronary disease who are asymptomatic or have
only mild angina, without documented left main disease,
the estimated cost-effectiveness ratios for PCI are greater
than $80,000 per QALY compared with medical therapy,
and are thus considered less favorable.
Because CEA research is new in the field of percutaneous
coronary intervention, CEA results are limited. The Com-
mittee underscores the need for cost containment and
careful decision making regarding the use of PCI strategies.
VIII. FUTURE DIRECTIONS
An exciting arena of active investigation relates to methods
of distal protection of the coronary vascular bed during PCI.
It is now recognized that distal embolization is an important
contributor to complications in patients undergoing SVG
intervention. Distal embolization is often due to dislodge-
ment of large, macroparticles from the friable graft, rather
than release of platelet-mediated aggregates. This compli-
cation can be prevented by the use of distal occlusion
balloons, such as the PercuSurge Guardwire, or with the use
of distal filters that trap the debris and remove it from the
distal circulation. A number of filter devices are currently
undergoing clinical evaluation, particularly in saphenous
vein graft disease and during carotid intervention.
Restenosis has also remained a vexing problem, despite
the benefits achieved with stent implantation. Novel ther-
apies have been developed, such as the application of
therapeutic ultrasound, photodynamic therapy, and systemic
administration of the anti-inflammatory agent tranilast. An
area of active investigation involves the use of balloon-
expandable stents coated with rapamycin, paclitaxol, or its
derivative. The local delivery of these agents has shown
promise in early clinical trials, and longer-term studies are
currently underway.
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